FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3135958598> ?p ?o ?g. }

• W3135958598 abstract "Background: Colorectal cancer (CRC) is the third most common cancer in Europe, with an annual increase in incidence ranging between 0.4 and 3.6% in various countries. Although the development of CRC was extensively studied, limited number of new therapies were developed in the last few years. Bevacizumab is frequently used as first- and second-line therapy for management of metastatic CRC (mCRC). The aim of this study is to present our experience with using bevacizumab beyond disease progression at different dosage levels in mCRC patients, in terms of overall survival, progression-free survival, time to treatment failure, and toxicities. Methods: We performed a consecutive retrospective analysis of patients with confirmed mCRC who were treated with bevacizumab at Prof Dr. Ion Chiricuta Institute of Oncology, Cluj-Napoca, Romania. We included patients who had received bevacizumab as first- or second-line therapy and further stratified them according to the dose administered as a second-line (either standard dose of 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks, or double dose of 10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks–depending on the classical chemotherapy partner). All patients had received bevacizumab beyond progression (BYP) which is defined as continuing bevacizumab administration through second-line treatment despite disease progression. In each group, we evaluated the prognostic factors that influenced survival and treatment outcome. Results: One hundred and fifty-one (151) patients were included in the study. Themedian age of patients receiving double dose bevacizumab (DDB) and standard dose bevacizumab (SDB) was 58 years (range 41–71) and 57 years (range 19–75), respectively. The median overall survival in the DDB group was 41 months (range 27–49) compared to 25 months (range 23–29) in the SDB group ( p = 0.01 log-rank test). First-line oxaliplatin-based treatment was used more frequently regardless of group, while irinotecan-based more frequently used as a second-line treatment ( p = 0.014). Both oxaliplatin- and irinotecan-based regimens were found to be suitable partners for BYP. Statistical analysis revealed that dose intensity, primary tumor location, and cumulative exposure to BYP had significant influence on survival. Conclusion: Doubling the dose of bevacizumab after first progression may improve survival in mCRC patients. Increasing bevacizumab dose intensity could override the prognostic impact of primary tumor location in patients receiving double the dose of bevacizumab after first disease progression." @default.
• W3135958598 created "2021-03-29" @default.
• W3135958598 creator A5013495023 @default.
• W3135958598 creator A5020856426 @default.
• W3135958598 creator A5022186173 @default.
• W3135958598 creator A5022186904 @default.
• W3135958598 creator A5027897849 @default.
• W3135958598 creator A5029654648 @default.
• W3135958598 creator A5031113578 @default.
• W3135958598 creator A5032466697 @default.
• W3135958598 creator A5040569354 @default.
• W3135958598 creator A5040652789 @default.
• W3135958598 creator A5040864132 @default.
• W3135958598 creator A5042894787 @default.
• W3135958598 creator A5050936496 @default.
• W3135958598 creator A5058742793 @default.
• W3135958598 creator A5061283632 @default.
• W3135958598 creator A5070291364 @default.
• W3135958598 creator A5073945265 @default.
• W3135958598 creator A5075600006 @default.
• W3135958598 creator A5086197477 @default.
• W3135958598 creator A5087600537 @default.
• W3135958598 date "2021-03-11" @default.
• W3135958598 modified "2023-10-18" @default.
• W3135958598 title "Doubling the Dose of Bevacizumab Beyond Progression in Metastatic Colorectal Cancer–the Experience of a Tertiary Cancer Center" @default.
• W3135958598 cites W1924916203 @default.
• W3135958598 cites W1967628954 @default.
• W3135958598 cites W1971440301 @default.
• W3135958598 cites W2002986768 @default.
• W3135958598 cites W2019607817 @default.
• W3135958598 cites W2025145463 @default.
• W3135958598 cites W2035426218 @default.
• W3135958598 cites W2061908201 @default.
• W3135958598 cites W2106090525 @default.
• W3135958598 cites W2107053205 @default.
• W3135958598 cites W2108819615 @default.
• W3135958598 cites W2116911901 @default.
• W3135958598 cites W2137417501 @default.
• W3135958598 cites W2157410007 @default.
• W3135958598 cites W2160373161 @default.
• W3135958598 cites W2165741055 @default.
• W3135958598 cites W2180809611 @default.
• W3135958598 cites W2404928889 @default.
• W3135958598 cites W2470575266 @default.
• W3135958598 cites W2471542599 @default.
• W3135958598 cites W2507923170 @default.
• W3135958598 cites W2589002968 @default.
• W3135958598 cites W2598390777 @default.
• W3135958598 cites W2621638238 @default.
• W3135958598 cites W2794202423 @default.
• W3135958598 cites W2807373925 @default.
• W3135958598 cites W2883876941 @default.
• W3135958598 cites W2885659166 @default.
• W3135958598 cites W2889646458 @default.
• W3135958598 cites W2892357411 @default.
• W3135958598 cites W2894330116 @default.
• W3135958598 cites W2895926103 @default.
• W3135958598 cites W2901082418 @default.
• W3135958598 cites W2901599446 @default.
• W3135958598 cites W2907344428 @default.
• W3135958598 cites W2942481282 @default.
• W3135958598 cites W2946089174 @default.
• W3135958598 cites W2950531100 @default.
• W3135958598 cites W2965867002 @default.
• W3135958598 cites W2993994776 @default.
• W3135958598 doi "https://doi.org/10.3389/fphar.2021.487316" @default.
• W3135958598 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7991840" @default.
• W3135958598 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33776758" @default.
• W3135958598 hasPublicationYear "2021" @default.
• W3135958598 type Work @default.
• W3135958598 sameAs 3135958598 @default.
• W3135958598 citedByCount "3" @default.
• W3135958598 countsByYear W31359585982022 @default.
• W3135958598 countsByYear W31359585982023 @default.
• W3135958598 crossrefType "journal-article" @default.
• W3135958598 hasAuthorship W3135958598A5013495023 @default.
• W3135958598 hasAuthorship W3135958598A5020856426 @default.
• W3135958598 hasAuthorship W3135958598A5022186173 @default.
• W3135958598 hasAuthorship W3135958598A5022186904 @default.
• W3135958598 hasAuthorship W3135958598A5027897849 @default.
• W3135958598 hasAuthorship W3135958598A5029654648 @default.
• W3135958598 hasAuthorship W3135958598A5031113578 @default.
• W3135958598 hasAuthorship W3135958598A5032466697 @default.
• W3135958598 hasAuthorship W3135958598A5040569354 @default.
• W3135958598 hasAuthorship W3135958598A5040652789 @default.
• W3135958598 hasAuthorship W3135958598A5040864132 @default.
• W3135958598 hasAuthorship W3135958598A5042894787 @default.
• W3135958598 hasAuthorship W3135958598A5050936496 @default.
• W3135958598 hasAuthorship W3135958598A5058742793 @default.
• W3135958598 hasAuthorship W3135958598A5061283632 @default.
• W3135958598 hasAuthorship W3135958598A5070291364 @default.
• W3135958598 hasAuthorship W3135958598A5073945265 @default.
• W3135958598 hasAuthorship W3135958598A5075600006 @default.
• W3135958598 hasAuthorship W3135958598A5086197477 @default.
• W3135958598 hasAuthorship W3135958598A5087600537 @default.
• W3135958598 hasBestOaLocation W31359585981 @default.
• W3135958598 hasConcept C121608353 @default.
• W3135958598 hasConcept C126322002 @default.
• W3135958598 hasConcept C141071460 @default.
• W3135958598 hasConcept C143998085 @default.

• next